PL1901736T3 - Kompozycja farmaceutyczna zawierająca symwastatynę i ezetymib - Google Patents

Kompozycja farmaceutyczna zawierająca symwastatynę i ezetymib

Info

Publication number
PL1901736T3
PL1901736T3 PL06762303T PL06762303T PL1901736T3 PL 1901736 T3 PL1901736 T3 PL 1901736T3 PL 06762303 T PL06762303 T PL 06762303T PL 06762303 T PL06762303 T PL 06762303T PL 1901736 T3 PL1901736 T3 PL 1901736T3
Authority
PL
Poland
Prior art keywords
ezetimibe
simvastatin
pharmaceutical composition
oxygen
present
Prior art date
Application number
PL06762303T
Other languages
English (en)
Inventor
Vesna Kroselj
Renata Lakse
Rebeka Toporisic
Joze Kastelic
Original Assignee
Krka Tovarna Zdravil D D Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34937786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1901736(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka Tovarna Zdravil D D Novo Mesto filed Critical Krka Tovarna Zdravil D D Novo Mesto
Publication of PL1901736T3 publication Critical patent/PL1901736T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
PL06762303T 2005-07-06 2006-06-30 Kompozycja farmaceutyczna zawierająca symwastatynę i ezetymib PL1901736T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05014680A EP1741427A1 (en) 2005-07-06 2005-07-06 Pharmaceutical composition comprising simvastatin and ezetimibe
EP06762303A EP1901736B1 (en) 2005-07-06 2006-06-30 Pharmaceutical composition comprising simvastatin and ezetimibe
PCT/EP2006/006369 WO2007003365A1 (en) 2005-07-06 2006-06-30 Pharmaceutical composition comprising simvastatin and ezetimibe

Publications (1)

Publication Number Publication Date
PL1901736T3 true PL1901736T3 (pl) 2010-09-30

Family

ID=34937786

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06762303T PL1901736T3 (pl) 2005-07-06 2006-06-30 Kompozycja farmaceutyczna zawierająca symwastatynę i ezetymib

Country Status (17)

Country Link
US (1) US8921352B2 (pl)
EP (2) EP1741427A1 (pl)
AT (1) ATE464882T1 (pl)
CA (1) CA2614347A1 (pl)
DE (1) DE602006013821D1 (pl)
DK (1) DK1901736T3 (pl)
EA (1) EA013266B1 (pl)
ES (1) ES2341731T3 (pl)
HR (1) HRP20100282T1 (pl)
NO (1) NO340496B1 (pl)
PL (1) PL1901736T3 (pl)
PT (1) PT1901736E (pl)
RS (1) RS51338B (pl)
SI (1) SI1901736T1 (pl)
UA (1) UA90521C2 (pl)
WO (1) WO2007003365A1 (pl)
ZA (1) ZA200800111B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
WO2008101723A2 (en) * 2007-02-23 2008-08-28 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
CA2708159C (en) 2007-12-10 2016-01-26 Ratiopharm Gmbh Pharmaceutical formulation comprising ezetimibe
EP2231118B2 (en) * 2007-12-17 2017-05-17 KRKA, tovarna zdravil, d.d., Novo mesto Suspension comprising non-micronized ezetimibe micro-particles
TR200806300A2 (tr) * 2008-08-22 2010-03-22 B�Lg�� Mahmut Çözünürlük artırıcı farmasötlk formulasyon
TR200806302A2 (tr) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2204170A1 (en) * 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
EP2216016A1 (en) * 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
WO2011002424A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
WO2011002422A2 (en) * 2009-07-02 2011-01-06 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
EP2448919A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
CN102266323B (zh) * 2011-08-04 2013-03-27 海南锦瑞制药股份有限公司 依折麦布和辛伐他汀组合物及其制备方法
KR102578578B1 (ko) * 2016-02-03 2023-09-14 삼성전자주식회사 암모니아수 내의 불순물 검출방법
JP7115825B2 (ja) * 2017-06-28 2022-08-09 日医工株式会社 エゼチミブ含有経口製剤及びその製造方法
JP2019014700A (ja) * 2017-07-11 2019-01-31 大原薬品工業株式会社 エゼチミブ含有口腔内崩壊錠及びその製造方法
PL425975A1 (pl) * 2018-06-19 2020-01-02 Invest Bielany Spółka Z Ograniczoną Odpowiedzialnością Złożona kompozycja farmaceutyczna do leczenia dyslipidemii i sposób jej wytwarzania
WO2022023206A1 (en) * 2020-07-27 2022-02-03 Krka, D.D., Novo Mesto Bilayer tablet comprising ezetimibe and atorvastatin
CN115227659B (zh) * 2022-08-19 2023-05-02 北京百奥药业有限责任公司 一种依折麦布辛伐他汀组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
ATE374641T1 (de) * 2001-01-26 2007-10-15 Schering Corp Kombinationen vom ppar-aktivator fenofibrat mit dem hemmer der sterol-absorption ezetimibe zur behandlung von kardiovaskulären indikationen
EP1241110A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
AU2002353659A1 (en) * 2001-12-18 2003-07-15 Synthon B.V. Simvastatin dosage forms
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
SI21400A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska družba d.d. Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze
AU2003259547A1 (en) 2003-07-31 2005-02-14 Hetero Drugs Limited Ezetimibe polymorphs
DE602004010817T2 (de) * 2003-08-05 2008-12-11 Zentiva, A.S. Verfahren zur stabilisierung von atorvastatin
US20060223882A1 (en) * 2005-03-23 2006-10-05 Venkataraman Sundaram Amorphous simvastatin

Also Published As

Publication number Publication date
CA2614347A1 (en) 2007-01-11
EA013266B1 (ru) 2010-04-30
NO340496B1 (no) 2017-05-02
EP1901736B1 (en) 2010-04-21
EP1901736A1 (en) 2008-03-26
US8921352B2 (en) 2014-12-30
ZA200800111B (en) 2008-12-31
HRP20100282T1 (hr) 2010-07-31
PT1901736E (pt) 2010-05-31
EP1741427A1 (en) 2007-01-10
EA200702416A1 (ru) 2008-04-28
SI1901736T1 (sl) 2010-08-31
US20080300233A1 (en) 2008-12-04
RS51338B (en) 2011-02-28
DK1901736T3 (da) 2010-08-16
UA90521C2 (uk) 2010-05-11
DE602006013821D1 (en) 2010-06-02
ES2341731T3 (es) 2010-06-25
WO2007003365A1 (en) 2007-01-11
NO20080627L (no) 2008-04-02
ATE464882T1 (de) 2010-05-15

Similar Documents

Publication Publication Date Title
ZA200800111B (en) Pharmaceutical composition comprising simvastatin and ezetimibe
EA201390409A1 (ru) Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием
WO2007051811A3 (en) Pharmaceutical use of substituted amides
MY147373A (en) Piperazine derivatives as antimalarial agents
WO2010030180A3 (en) Peptide formulations and uses thereof
UA94901C2 (ru) Антибактериальные производные пиперидина
MY150958A (en) Compounds for the treatment of multi-drug resistant bacterial infections
HK1084582A1 (en) Stable solid medicinal composition for oral administration
BR0314612A (pt) Composição farmacêutica estabilizada, contendo excipientes básicos
WO2007112000A3 (en) Treatment of pain
EP2392322A3 (en) Dosing regimes for trans-clomiphene
WO2007112272A3 (en) Formulations of low dose diclofenac and beta-cyclodextrin
EP2648704B1 (en) Anti-microbial composition
IL192611A0 (en) Biologically active composition comprising ethylcellulose
NZ591204A (en) Pharmaceutical compositions and methods for stabilizing the same
WO2007062333A3 (en) New pleuromutilin derivative and its use
EP2801359A3 (en) The use of nicotine for the treatment of sepsis in humans caused by antibiotic
EP1713439B1 (en) Pharmaceutical preparation for the oral cavity
EA201100104A1 (ru) Фармацевтическая композиция, содержащая статин
BRPI0407529A (pt) uso de r-10-hidróxi-10,11-dihidro-carbamazepina em dor neuropática
WO2007138233A3 (fr) Utilisation du zatosetron pour le traitement de la rosacee
MY174362A (en) Nephelium lappaceum extracts for cosmeceutical and nutraceutical applications
CY1110814T1 (el) Νεα υποκατεστημενα αρυλοεξαδιενικα οξεα και εστερες αυτων τα οποια μπορουν να χρησιμοποιηθουν για την αγωγη και προληψη του διαβητη, δυσλιπιδαιμιας και αθηροσκληρωσης, φαρμακευτικες συνθεσεις που τα περιλαμβανουν και διεργασιες για την παρασκευη αυτων
HRP20090102T3 (en) Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof
MX2009002254A (es) Dosis de bifeprunox para tratar esquizofrenia.